Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes

This publication has 49 references indexed in Scilit:

• Experimental solid tumour activity ofN-[2-(dimethylamino)ethyl]-acridine-4-carboxamide
  Cancer Chemotherapy and Pharmacology, 1995
• Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic test systems
  Mutagenesis, 1995
• Mutagenicity and carcinogenicity of topoisomerase-interactive agents
  Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994
• potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: Comparison to salmonella responses
  Environmental and Molecular Mutagenesis, 1994
• Integration of simian virus 40 into cellular DNA occurs at or near topoisomerase II cleavage hot spots induced by VM-26 (teniposide).
  Molecular and Cellular Biology, 1993
• Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro
  Mutagenesis, 1990
• A Special Role for Amsacrine in the Treatment of Acute Leukemia
  Cancer Investigation, 1989
• Inverse correlation between bacterial frameshift mutagenicity and yeast mitochondrial effects of antitumour anilinoacridines
  Chemico-Biological Interactions, 1985
• Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells
  British Journal of Cancer, 1984
• Multinucleate Cells and Micronucleus Formation in Cultured Human Cells Exposed to 12 MeV Protons and γ-rays
  International Journal of Radiation Biology, 1980